Ciphergen Biosystems, NIDCD, Nonlinear Dynamics, Proteomic Research Services, Charles River Proteomics Services | GenomeWeb

Ciphergen Forecasts Disappointing Q2 Revenues, Plans Cuts in Biosystems Business

Ciphergen Biosystems announced late Wednesday night that it expects a significant drop in revenues for the second quarter and that it plans to cut costs in its Biosystems division. The company’s stock plunged to a low of $3.95 per share on the heels of the news, a 40 percent drop in value from its Wednesday close of $7.32.

Ciphergen estimates revenues of $10 to $11 million for the quarter ending June 30, down from $14.3 million during the same period last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.